Cxbladder is a suite of non-invasive genomic urine tests optimized for the risk stratification of urothelial cancer in patients presenting with hematuria and those being monitored for recurrent non-muscle invasive bladder cancer (NMIBC).
The tests help you improve the overall patient experience, while prioritizing your time and clinical resources to optimize practice workflow and improve efficiency.
Hematuria evaluation
Cxbladder Triage and Detect are optimized for the risk stratification of urothelial cancer in patients presenting with hematuria. The tests help de-intensify clinical work-up in patients with a low probability Cxbladder test result, reducing the need for referral and invasive procedures, while prioritizing those that require immediate care.
Featured resource
Real-World Implementation of Biomarkers for Microhematuria Workup
Presented by Dr. Ronald Loo & Dr. Christopher Filson, Kaiser Permanente
Dr. Ronald Loo and Dr. Christopher Filson join Dr. Zachary Klaassen to discuss the real-world implementation of Cxbladder Triage within the Kaiser Health System for risk stratification, including the results of a published study of over 3,300 patients.
Surveillance
Cxbladder Monitor is a non-invasive surveillance alternative that can reduce the burden of repeated cystoscopy in NMIBC patients with a low risk of recurrent urothelial cancer, improving comfort and compliance.
Featured resource
Survey: Surveillance Patients Show Strong Interest in Non-Invasive Test Options.
In December 2023, using the Bladder Cancer Advocacy Network’s (BCAN’s) Patient Survey Network, we surveyed 1,507 US patients being monitored for NMIBC.
Optimize your clinical practice while improving the patient experience
The Cxbladder suite helps you prioritize your time and clinical resources on those that need it the most, streamlining practice workflow and increasing overall efficiency.
Cxbladder works for both you and the patient. Spare patients with a low probability of urothelial cancer the discomfort, anxiety and risks of an invasive procedure, while optimizing your clinical practice while delivering the best patient experience possible.
Optimize your clinical practice while improving the patient experience
The Cxbladder suite helps you prioritize your time and clinical resources on those that need it the most, streamlining practice workflow and increasing overall efficiency.
Cxbladder works for both you and the patient. Spare patients with a low probability of urothelial cancer the discomfort, anxiety and risks of an invasive procedure, while optimizing your clinical practice while delivering the best patient experience possible.
Cxbladder is a precision test that delivers exceptional performance and clinically actionable results
Cxbladder is an objective test with high sensitivity and NPV.
The Cxbladder suite is supported by an evidence portfolio that includes over 25 peer reviewed publications in leading medical journals.
Cxbladder Triage is now included in the AUA/SUFU Microhematuria Guideline with supporting Level A Evidence.*
The Cxbladder suite of tests have been used by over 5,000 urologists in more than 100,000 patients.
Start your Cxbladder journey
Contact our customer service team
Learn more about the Cxbladder suite and how to implement it in your practice.
How Cxbladder works
The sampling process
Cxbladder's non-invasive urine sampling system is easy for patients to use, streamlining deployment in-clinic.
The science
Cxbladder is an objective test with high sensitivity and NPV that delivers exceptional performance and clinically actionable results. The test works at a molecular level, analyzing biomarker genes to help risk stratify urothelial cancer.
The test report
The Cxbladder test report have been developed in consultation with leading urologists and provides the patient’s Cxbladder score, alongside an interpretation of the results and an assay description.
Featured Resources
Platform Reduces Unnecessary Cystoscopies for Hematuria
Dr. Zachary Klaassen interviews Dr. John Sfakianos about implementing the Cxbladder platform for microhematuria risk stratification and bladder cancer surveillance. Dr. Sfakianos discusses how high-quality biomarkers address the longstanding need to avoid over-diagnosing patients with microhematuria, where historically everyone received cystoscopy despite most having no significant findings.
Advancing Microhematuria Evaluation: The Impact of Urinary Biomarkers and Updated Guidelines
Dr. Jay Raman and Dr. Yair Lotan sit down with Dr. Zachary Klaassen to discuss the latest developments in microhematuria evaluation. Topics include the unmet need in risk stratifying patients, the evolution of the AUA/SUFU Microhematuria Guideline from 2020 to 2025, and the role of urinary biomarkers in optimizing patient care, including Cxbladder Triage, a test now included in the Guideline*.
Real-World Implementation of Biomarkers for Microhematuria Workup
Kaiser Permanente's Dr. Ronald Loo and Dr. Christopher Filson join Dr. Zachary Klaassen to discuss the real-world implementation of Cxbladder Triage within the Kaiser Health System for risk stratification, including the results of a published study of over 3,300 patients.
Adopting Cxbladder in your clinical practice
Optimize your clinical resources and workflow while improving the patient experience
Learn more about the benefits of integrating Cxbladder into your practice workflow.
Cxbladder is available around the world
Cxbladder is available in the United States, and in countries across Asia and South America. Cxbladder is also available in New Zealand, Australia, and Israel.
Latest news
Clinical Value of Cxbladder to Feature at UAA 2025
New clinical evidence demonstrating Cxbladder’s clinical value in hematuria evaluation and surveillance is set to be presented at the 22nd Urological Association of Asia Congress in Taipei, Taiwan, 14-17 August.
Cxbladder Bulletin - July 2025
Pacific Edge invites you to read the July 2025 edition of the Cxbladder Bulletin clinician newsletter.
Medicare Coverage Update for US Cxbladder Customers
Novitas has finalized an LCD for Genetic Testing in Oncology that removed coverage for Medicare beneficiaries for Cxbladder tests effective on April 24, 2025. In this update we discuss our response and what this means for US Cxbladder customers going forward.
Cxbladder Bulletin - April 2025
Pacific Edge invites you to read the April 2025 edition of the Cxbladder Bulletin clinician newsletter.
References
* Barocas DA, Lotan Y, Matulewicz RS, Raman JD, Westerman ME, Kirkby E, Pak L, Souter L. Updates to Microhematuria: AUA/SUFU Guideline (2025). J Urol. 0(0). doi: 10.1097/JU.0000000000004490.